Olux-e Generic Name & Formulations
Clobetasol propionate 0.05%; emulsion aerosol foam.
Olux-e Dosage and Administration
≥12yrs: apply thin layer to affected area(s) twice daily (AM & PM); max 50g/week or 21 capfuls/week and 2 consecutive week's treatment per course. Discontinue when control is achieved. Wash hands after application. Do not occlude.
<12yrs: not recommended.
Olux-e Boxed Warnings
Not for oral, ophthalmic, or intravaginal use. Avoid use on face, axillae, groin, or other intertriginous areas. Do not use for diaper dermatitis or on pre-existing skin atrophy. Risk of HPA axis suppression with high-potency steroids, prolonged use, application to large surface area, use of occlusive dressings, altered skin barrier, liver failure, young age; discontinue gradually, reduce dose, or substitute with less potent corticosteroid if occurs. Increased risk of posterior subcapsular cataracts and glaucoma; monitor for visual symptoms. Treat infection if present; discontinue if infection persists or worsens. Avoid abrupt cessation in chronic use. Reevaluate periodically. Product is flammable. Pregnancy. Nursing mothers.
Olux-e Adverse Reactions
Burning, stinging, pruritus, erythema, skin atrophy, folliculitis, dermal cracking and fissuring, telangiectasia, striae; allergic contact dermatitis (discontinue if irritation occurs), HPA axis suppression (esp. in children); rare: Cushing's syndrome, hyperglycemia.
Olux-e Clinical Trials
Olux-e Patient Counseling